Table 2. Key urinary metabolites responsible for the discrimination of MDD patients and HCs.
Metabolites | VIP | p-value | Adjusted p-value | Fold change | Platform |
Young | |||||
Homovanillic acid | 1.15 | 0.014 | 0.045 | 1.76 | GC-MS |
L-Leucine | 1.17 | 0.014 | 0.046 | 1.65 | GC-MS |
4-Deoxythreonic acid | 1.06 | 8.49E-06 | 0.00018 | 1.64 | GC-MS |
4-Deoxyerythronic acid | 1.09 | 0.000075 | 0.0011 | 1.61 | GC-MS |
Methylmalonic acid | 1.04 | 0.0039 | 0.015 | 1.54 | GC-MS |
L-Cysteine | 1.11 | 0.0024 | 0.011 | 1.44 | GC-MS |
Formic acid | 1.23 | 0.005 | 0.019 | 0.68 | NMR |
Azelaic acid | 1.06 | 0.000057 | 0.001 | 0.17 | GC-MS |
Young/Middle-aged | |||||
1-Methylinosine | 1.22/1.31 | 0.00034/0.00025 | 0.0027/0.0013 | 2.15/1.99 | GC-MS |
Citric acid | 1.23/1.23 | 0.00027/0.002 | 0.002/0.0072 | 0.68/0.72 | NMR |
Ethanolamine | 1.29/1.24 | 0.011/0.00098 | 0.038/0.0043 | 2.02/1.89 | GC-MS |
Hypoxanthine | 1.22/1.64 | 2.79E-10/1.09E-08 | 2.45E-07/4.83E-06 | 3.79/3.59 | GC |
Indoxyl sulfate | 1.29/1.34 | 0.00011/0.000039 | 0.0012/0.00028 | 2.06/1.76 | GC |
L-Tyrosine | 1.17/1.56 | 2.96E-06/0.0015 | 8.6E-05/0.006 | 2.39/2.95 | GC |
Oxoglutaric acid | 1.74/1.06 | 0.008/4.97E-07 | 0.03/7.28E-06 | 0.75/0.86 | NMR |
Pseudouridine | 1.21/1.48 | 0.00013/0.00023 | 0.0013/0.0012 | 2.2/2.29 | GC |
Quinolinic acid | 1.15/1.41 | 0.00054/0.0034 | 0.0036/0.011 | 1.94/1.96 | GC |
Uracil | 1.24/1.39 | 0.0026/0.0023 | 0.011/0.0077 | 1.9/1.71 | GC |
Middle-aged | |||||
N-Methylnicotinamide | 1.83 | 0.001 | 0.0042 | 2.08 | NMR |
L-Phenylalanine | 1.32 | 0.01 | 0.028 | 1.52 | GC-MS |
L-Lactic acid | 1.21 | 1.12E-06 | 0.000014 | 0.8 | NMR |
Succinic acid | 1.05 | 0.000015 | 0.00015 | 0.86 | NMR |
3-Hydroxyphenylacetic acid | 1.03 | 0.0046 | 0.013 | 1.94 | GC-MS |
ap-value was obtained from the nonparametric Mann-Whitney U test.
badjusted p-value was obtained using Benjamini and Hochberg False Discovery Rate.
cvalues less than 1.0 indicated significantly lower levels in MDD patients; values higher than 1.0 indicated significantly higher levels in MDD patients.